Insulin-like growth factor 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Formation of the Quinonoid Intermediate PLP acts as an 'electron sink' absorbing delocalized electron density during the reaction intermediates (countering the excess electron density on the deprotonated a-carbon). PLP facilitates the enzyme activity, increasing the acidity of the alpha carbon by stabilizing the conjugate base. The PLP-stabilized carbanion intermediate formed is the quinonoid intermediate. Tyrosine and PLP stabilized 3C-Ring formation PLP and Tyrosine stabilize negative charges during deprotonation. Tyrosine attacks the sulfur bound carbon, allowing S(CH3)(Ado) to leave, and during ring formation, Tyrosine leaves. Note inhibitors AVG and AMA bind PLP to form a ketimine and oxime respectively (whose reverse reactions are much less favorable) and prevent the ACC synthase catalyzed reaction with SAM.
Methods have been developed to purify DNA from organisms, such as phenol-chloroform extraction, and to manipulate it in the laboratory, such as restriction digests and the polymerase chain reaction. Modern biology and biochemistry make intensive use of these techniques in recombinant DNA technology. Recombinant DNA is a man-made DNA sequence that has been assembled from other DNA sequences. They can be transformed into organisms in the form of plasmids or in the appropriate format, by using a viral vector. The genetically modified organisms produced can be used to produce products such as recombinant proteins, used in medical research, or be grown in agriculture.
Osmium (76Os) has seven naturally occurring isotopes, five of which are stable: 187Os, 188Os, 189Os, 190Os, and (most abundant) 192Os. The other natural isotopes, 184Os and 186Os, have extremely long half-lives (1.12×1013 years and 2.0×1015 years, respectively) and for practical purposes can be considered to be stable as well. 187Os is the daughter of 187Re (half-life 4.12×1010 years) and is most often measured by the 187Os/188Os ratio. This ratio, as well as the 187Re/188Os ratio, have been used extensively in dating terrestrial as well as meteoric rocks. It has also been used to measure the intensity of continental weathering over geologic time and to fix minimum ages for stabilization of the mantle roots of continental cratons. There are also 31 artificial radioisotopes, the longest-lived of which are 194Os with a half-life of 6.0 years, 185Os with 92.95 days, and 191Os with 14.99 days; others are under 30 hours, with most under seven minutes. There are also 19 listed nuclear isomers, the longest-lived of which is 191mOs with a half-life of 13.10 hours. All isotopes and nuclear isomers of osmium are either radioactive or observationally stable, meaning that they are predicted to be radioactive but no actual decay has been observed.
13 July Air pollution particles are shown to reduce insects' ability to find food and a mate, in experiments. This may be contributing to the dramatic fall in global insect populations, the scientists conclude. Scientists use CRISPR gene-editing to reduce the lignin content in poplar trees by as much as 50%, offering a potentially more sustainable method of fiber production. 14 July – The Indian Space Research Organisation (ISRO) successfully launches its Chandrayaan-3 spacecraft towards the Moon, aiming to become the fourth nation to achieve a soft landing on the lunar surface. 17 July – Astronomers of the Breakthrough Listen project report the development of a novel technique that can help distinguish between potential deliberate artificial alien signals and Earth-based radio interference via unique signatures from passing through ionized plasma of interstellar medium. 19 July – Astronomers report the discovery of a bizarre 'two-faced' star, with one side made up of hydrogen and the other consisting of helium. The object, designated ZTF J203349.8+322901.1, is a white dwarf located about 1,000 light years away. 18 July – The first example of naturally occurring graphene is reported, at a gold mine in South Africa. 19 July – Researchers report the discovery of self-healing of fatigue cracks in metals in vacuum.
Sources: en.wikipedia.org
The Le Havre Palace of Justice is located on the Boulevard de Strasbourg. With its annex, it includes a high court, a juvenile court, and a commercial court. The city also has a Labour Court and District Court. Among the legal services offered there are legal aid services and the application of penalties. Le Havre depends on the Court of Appeal of Rouen. The prison, which dates from the Second Empire, was completely destroyed in 2012. The new prison for Le Havre was completed in 2010 at Saint-Aubin-Routot east of the Le Havre agglomeration. It has an area of 32,000 m2 on a site of 15 hectares and can accommodate 690 people. The Hospital Group of Havre is a public health facility managed by a supervisory board chaired by the Mayor of Le Havre. Its main structures are Flaubert Hospital (the oldest, located downtown), the Monod Hospital (in Montivilliers), the Pierre Janet Hospital (psychiatry), the house for adolescents, day hospitals, and seniors' residences. It is the largest employer in the CODAH. Built in 1987, the Jacques Monod Hospital offers a full range of care in medicine, surgery, gynecology, obstetrics, pediatrics, geriatrics, mental health follow-up care, rehabilitation, reintegration, and public health. Finally, there are several private clinics that offer complete care: the private clinic of the Estuary groups together the old clinics of Petit Colmoulins and François I. The private clinic of Ormeaux is located in the neighbourhood of Eure.
=== World Health Organization === Vaccines developed for multinational distribution via the United Nations Children's Fund (UNICEF) require pre-qualification by the WHO to ensure international standards of quality, safety, immunogenicity, and efficacy for adoption by numerous countries. The process requires manufacturing consistency at WHO-contracted laboratories following Good Manufacturing Practice (GMP). When UN agencies are involved in vaccine licensure, individual nations collaborate by 1) issuing marketing authorization and a national license for the vaccine, its manufacturers, and distribution partners; and 2) conducting postmarketing surveillance, including records for adverse events after the vaccination program. The WHO works with national agencies to monitor inspections of manufacturing facilities and distributors for compliance with GMP and regulatory oversight. Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.
==== Sanctions ==== On 15 September, the company issued a public apology for the contaminated powdered milk; Sanlu was ordered to halt production, and to destroy all unsold and recalled products. Authorities reportedly seized 2,176 tons of powdered milk in Sanlu's warehouses. An estimated 9,000 tons of product had been recalled. Tian Wenhua, chairwoman and general manager of Sanlu and Secretary of the Sanlu Communist Party chapter was stripped of her party and functional posts during an extraordinary meeting of the Hebei provincial standing committee of the CCP; four Shijiazhuang officials, including vice mayor in charge of food and agriculture, Zhang Fawang, were reportedly removed from office. Shijiazhuang Mayor Ji Chuntang resigned on 17 September. Li Changjiang, minister in charge of the AQSIQ, was forced to resign on 22 September after the State Council inquest concluded he was responsible for the "negligence in supervision". Investigators also blamed the Shijiazhuang government. Local Party Secretary Wu Xianguo was fired on the same day.
The hundreds of steroids found in animals, fungi, and plants are made from lanosterol (in animals and fungi; see examples above) or cycloartenol (in other eukaryotes). Both lanosterol and cycloartenol derive from cyclization of the triterpenoid squalene. Lanosterol and cycloartenol are sometimes called protosterols because they are the starting compounds for all other steroids. Steroid biosynthesis is an anabolic pathway which produces steroids from simple precursors. A unique biosynthetic pathway is followed in animals (compared to many other organisms), making the pathway a common target for antibiotics and other anti-infection drugs. Steroid metabolism in humans is also the target of cholesterol-lowering drugs, such as statins. In humans and other animals the biosynthesis of steroids follows the mevalonate pathway, which uses acetyl-CoA as building blocks for dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP). In subsequent steps DMAPP and IPP conjugate to form farnesyl diphosphate (FPP), which further conjugates with each other to form the linear triterpenoid squalene. Squalene biosynthesis is catalyzed by squalene synthase, which belongs to the squalene/phytoene synthase family. Subsequent epoxidation and cyclization of squalene generate lanosterol, which is the starting point for additional modifications into other steroids (steroidogenesis). In other eukaryotes, the cyclization product of epoxidized squalene (oxidosqualene) is cycloartenol.
Circularly polarised ultraviolet light has been shown to generate L-excesses in crystallising amino acids for experimental conditions mimicking alteration on asteroids, and this is thought to be the dominant extraterrestrial source of chiral symmetry breaking (i.e., the favouring of one enantiomer over another). It is notable that only excesses of the L-enantiomer have been observed in extraterrestrial amino acids, suggesting that the abiotic process responsible for enantiomeric enrichments may be the original source of the L-amino acid selectivity currently observed in terrestrial life.
Sources: en.wikipedia.org
If there are to be multiple ICP-MS instruments running for long periods of time, then it will most likely be beneficial for the laboratory to install a bulk or micro bulk argon tank which will be maintained by a gas supply company, thus eliminating the need to change out tanks frequently as well as minimizing loss of argon that is left over in each used tank as well as down time for tank changeover. Helium can be used either in place of, or mixed with, argon for plasma generation. Helium's higher first ionisation energy allows greater ionisation and therefore higher sensitivity for hard-to-ionise elements. The use of pure helium also avoids argon-based interferences such as ArO. However, many of the interferences can be mitigated by use of a collision cell, and the greater cost of helium has prevented its use in commercial ICP-MS.
=== Anhydrous structure === Anhydrous Dy(ClO4)3 crystallizes in the hexagonal crystal system, space group P63/m (No. 176). It is isostructural with the anhydrous perchlorates of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Ho and Er, and belongs to a structure family related to the UCl3 type. In this structure the Dy3+ centres are nine-coordinate. The coordination environment is formed by oxygen atoms belonging to perchlorate groups, which act as multidentate ligands and generate a three-dimensional channel-containing framework. Across the lanthanide series, the lattice parameters decrease systematically because of the lanthanide contraction.
Serine hydroxymethyltransferase can decompose serine into formaldehyde and glycine, according to the reaction HOCH2CH(NH2)CO2H → CH2O + H2C(NH2)CO2H. Methylotrophic microbes convert methanol into formaldehyde and energy via methanol dehydrogenase: `CH3OH → CH2O + 2e− + 2H+ Other routes to formaldehyde include oxidative demethylations, semicarbazide-sensitive amine oxidases, dimethylglycine dehydrogenases, lipid peroxidases, P450 oxidases, and N-methyl group demethylases. Formaldehyde is catabolized by alcohol dehydrogenase ADH5 and aldehyde dehydrogenase ALDH2.
== SR == sr – (s) Serbian language (ISO 639-1 code) Sr – (s) Strontium SR (i) Sound Reinforcement Supply Route (s) Suriname (ISO 3166 digram) (i) Sveriges Radio (Swedish Radio Ltd) SR – (i) Sustained release of a drug SRAM (p) Scott (King), Ray (Day), SAM (Patterson) — founders of bicycle component manufacturer SRAM Corporation (p) Static Random Access Memory ("ess-ram") SR-ATGW – (i) Short-Range Anti-Tank Guided Weapon SRB – (i) Solid Rocket Booster SRBM – (i) Short-Range Ballistic Missile (cf. IRBM, ICBM) SRC – (i) Scheduled Removal Component srd – (s) Sardinian language (ISO 639-2 code) SRD (i) Science Requirements Document (s) Surinam dollar (ISO 4217 currency code) SRE - (i) Site Reliability Engineer(ing) SREL – (i) Savannah River Ecology Laboratory SRG (i) SACEUR Rover Group Special Republican Guard SRGW – (i) Short-Range Guided Weapon SRL (i) Savannah River Laboratory Single Rocket Launcher Survival Research Labs SRM – (i) Specified Risk Material(s) srp – (s) Serbian language (ISO 639-2 code) SRS – (i) Savannah River Site SRTP – (i) [Secure Real-time Transport Protocol]
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.